TY - JOUR
T1 - Chronic myeloid leukaemia
AU - Cortes, Jorge
AU - Pavlovsky, Carolina
AU - Saußele, Susanne
N1 - Funding Information:
JC reports grants and personal fees from Novartis, Pfizer, Takeda, and Sun Pharma; and grants from Bristol Myers Squibb, all outside the submitted work. CP reports grants and personal fees from Novartis and Pint Pharma; and personal fees from Bristol Myers Squibb and Pfizer, all outside the submitted work. SS reports grants and personal fees from Novartis, Bristol Myers Squibb, and Incyte; and personal fees from Pfizer, all outside the submitted work.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/11/20
Y1 - 2021/11/20
N2 - Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy. Achieving this goal requires an adequate understanding of the patient's treatment goals, careful monitoring for the achievement of optimal response hallmarks, implementation of proper interventions according to the attainment of such endpoints, adequate recognition and management of adverse events, and acknowledgment of the relevance of comorbidities. Treatment with tyrosine-kinase inhibitors, once considered lifelong, has become terminable for at least some patients, and promising new agents are emerging for those whose disease does not respond to any of the multiple therapeutic options currently available. If these advances reach all patients with chronic myeloid leukaemia, cure might eventually become a reality in most instances.
AB - Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy. Achieving this goal requires an adequate understanding of the patient's treatment goals, careful monitoring for the achievement of optimal response hallmarks, implementation of proper interventions according to the attainment of such endpoints, adequate recognition and management of adverse events, and acknowledgment of the relevance of comorbidities. Treatment with tyrosine-kinase inhibitors, once considered lifelong, has become terminable for at least some patients, and promising new agents are emerging for those whose disease does not respond to any of the multiple therapeutic options currently available. If these advances reach all patients with chronic myeloid leukaemia, cure might eventually become a reality in most instances.
UR - http://www.scopus.com/inward/record.url?scp=85119262309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119262309&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)01204-6
DO - 10.1016/S0140-6736(21)01204-6
M3 - Review article
C2 - 34425075
AN - SCOPUS:85119262309
SN - 0140-6736
VL - 398
SP - 1914
EP - 1926
JO - The Lancet
JF - The Lancet
IS - 10314
ER -
